With two approved therapeutics and the field working to develop the next generation of IPF drugs, the opportunity to become the undisputed, most effective, and disease-modifying agent on the market has never been greater.
What’s new and unmissable for 2022:
- 29 brand new industry speakers, as well as returning KOLs including Fernando Martinez, Naftali Kaminski, Toby Maher, and many more
- 6 interactive workshops to delve into IPF’s hottest topics, discuss challenges, pose your burning questions to leading experts, and highlight the respiratory pipeline development opportunities including SSc-ILD, COPD, and COVID fibrosis
- A brand-new Tissue Repair and Regeneration Day, with dedicated sessions on halting and reversing disease progression to rethinking senescence to unlocking cell therapies. Get more insight than ever before on evolving basic science and regenerative therapy opportunities
- Exclusive presentations on the regulatory and patient perspectives to inform clinical trial design and future therapeutic development
Get in the room with your team to meet peers and KOLs and take away critical insights at the world’s most comprehensive and dedicated IPF conference. Confirmed attendees include AbbVie, Boehringer Ingelheim, Bayer, BMS, Genentech, Galecto, Novartis, and Trevi Therapeutics.
From navigating pathophysiology and pathobiology, exploring all available target opportunities to leveraging synthetic control arms in clinical trials; this is a conversation you won’t want to miss to transform your IPF research.
To know more visit: https://ter.li/6yo2nd